Order Article Reprints

Domański P, Piętak M, Kruczyk B, Jarosińska J, Mydlak A, Demkow T, Darewicz M, Sikora-Kupis B, Dumnicka P, Kamzol W, et al. Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study. Biomedicines. 2024; 12(2):413. https://doi.org/10.3390/biomedicines12020413

Domański, Piotr, Mateusz Piętak, Barbara Kruczyk, Jadwiga Jarosińska, Anna Mydlak, Tomasz Demkow, Marta Darewicz, Bożena Sikora-Kupis, Paulina Dumnicka, Wojciech Kamzol, and et al. 2024. "Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study" Biomedicines 12, no. 2: 413. https://doi.org/10.3390/biomedicines12020413

Domański, P., Piętak, M., Kruczyk, B., Jarosińska, J., Mydlak, A., Demkow, T., Darewicz, M., Sikora-Kupis, B., Dumnicka, P., Kamzol, W., & Kucharz, J. (2024). Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study. Biomedicines, 12(2), 413. https://doi.org/10.3390/biomedicines12020413